TABLE 2.

Prevalence and sow-associated mean group levels of anti-PCV2 IgG and serum neutralizing antibodies for nonvaccinated and noninoculated sows (group 1), sows vaccinated at 28 days of gestation (groups 2 and 3), and sows oronasally inoculated with PCV2b (groups 3 and 4) at 56 days of gestation

Group	No. of sows with IgG antibody/no. of sows in group (mean S/P ratio ± SE) on day of gestation				No. of sows with neutralizing antibody/no. of sows in group (mean antibody levela ± SE) on day of gestation
	28	56	84	112	56	112
1	0/3 (0.00 ± 0.00)	0/3 (0.00 ± 0.00)	0/3 (0.00 ± 0.00)	0/3 (0.00 ± 0.00)	0/3 (1.81 ± 0.00)	0/3 (1.81 ± 0.00)
2	0/3 (0.00 ± 0.00)	2/3 (0.29 ± 0.15)	2/3 (0.28 ± 0.11)	3/3 (0.56 ± 0.05)	3/3 (2.31 ± 0.20)	3/3 (2.41 ± 0.00)
3	0/3 (0.00 ± 0.00)	2/3 (0.08 ± 0.15)	2/3 (0.29 ± 0.15)	3/3 (0.43 ± 0.11)	2/3 (2.11 ± 0.30)	3/3 (2.51 ± 0.10)
4	0/3 (0.00 ± 0.00)	0/3 (0.00 ± 0.00)	1/3 (0.23 ± 0.21)	3/3 (0.40 ± 0.12)	0/3 (1.81 ± 0.00)	3/3 (2.81 ± 0.44)

^aMean log-transformed serum neutralizing antibody level.